Meeting Overview

The 2012 Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology will be held at the Hilton Hotel in Washington, DC, from November 15 through November 18, 2012. In addition to a stimu-lating Education Day and the abstract driven scientific sessions of the main meeting, SNO is pleased to offer a number of exciting new fea-tures for this year’s meeting, including a special biomarkers course, a keynote address from Dr. Bert Vogelstein, a new Public Service Award, the inaugural Abhijit Guha Award and Lecture, expanded sessions for Young Investigators and an evening satellite on 1p/19q codeleted anaplastic gliomas.

The meeting is designed for neurosurgeons, neuro-oncologists, medical oncologists, neuropathologists, radiation oncologists, neuroradiologists, pediatricians, laboratory scientists, nurses and other specialists involved in the research, diagnosis, care and treatment of central nervous system tumors.

Educational Objectives

After attending the conference, participants should be able to:

• Construct a list of current studies on epidemiologic factors associated with central nervous system tumors (knowledge);

• Using neurocognitive intervention strategies, create a plan to diminish the impact of brain tumors and their treatments on patients and quality of life (knowledge, competence, performance, patient outcomes);

• Discuss new research on cell biology, tumor microenvironment, signal transduction, genomic, epigenomic, proteomic and metabolic complexity, and factors associated with angiogenesis and invasion in brain tumors (knowledge);

• Apply therapeutic strategies related to new research on genes that are associated with brain tumors (knowledge, competence, performance);

• Discuss new research on CNS antitumor immunoreactivity (knowledge);

• Apply advances in imaging and neuropathology to diagnose and measure response to therapy for patients with CNS tumors (knowledge, competence, performance);

• Use advances in pharmacology, experimental therapeutics, biologic therapies, and radiobiology to improve future therapies for patients with CNS tumors (knowledge, competence, performance);

• Utilize results of new clinical studies for central nervous system tumors for improved patient outcomes (knowledge, competence, performance, patient outcomes);

• Utilize symptom management initiatives to improve quality of life for brain tumor patients (knowledge, competence, performance).

The 17th Annual Scientific Meeting & Education Day of the Society for Neuro-Oncology

November 15-18, 2012Hilton Hotel, Washington DC

Target Audience

This conference should be of value to neuro-oncologists, medical oncol-ogists, neurosurgeons, pediatric neuro-oncologists, neuroradiologists, neuropathologists, radiation oncologists, neuropsychologists, epidemi-ologists, nurses, psychologists, basic and translational scientists.

Educational Methods

Lectures, Question-and-Answer Sessions, Panel Discussions, Posters, Other.

Evaluation

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit Designation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas MD Anderson Cancer Center and the Society for Neuro-Oncology. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 27.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The presentations included in the Quality of Life Interventions section have been designated by The University of Texas MD Anderson Cancer Center for 3.75 AMA PRA Category 1 CreditsTM in medical ethics and/or professional responsibility.

CME Certificates and Attendance Verification Certificates

Certificates awarding AMA PRA Category 1 CreditsTM or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a

CME Verification Form. Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

The University of Texas MD Anderson Cancer Center has implement-ed a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Registration Information

The early-bird deadline for advance registration is October 15, 2012. There are three ways to register:

On-Line at: www.soc-neuro-onc.org

Mail to:

SNOPO Box 273296

Houston, TX 77277

Fax to: (713) 583-1345

The following forms of payment are accepted:• Checks or money orders made payable to SNO• Credit Card (MasterCard, VISA, Discover, Diners Club and American Express)• Cash on-site ($50 surcharge applies if not pre-registered)

The registration fee for the Education Day (November 15) includes all course materials, a continental breakfast and a box lunch. The registra-tion fee for the Scientific Meeting (November 16-18) includes all course materials, daily continental breakfasts, box lunches, receptions, and the conference banquet. SNO will provide a receipt and confirmation of your registration.

Special Assistance: Contact SNO at (713) 349-0952 if you have any special dietary or ADA accommodation needs.

Refunds/Cancellations

The registration fee, minus a $50 administrative handling fee, is refund-able if a written or email request is received on or before November 1, 2012. No refunds will be given after this date. The request for a registration refund must include the tax identification number of the company or institution if the registration was paid by a company or an institution check. Although no refunds will be granted after November 1, 2012, registration may be transferred to a colleague.

In case of meeting cancellation, liability of the Society for Neuro-Oncology is limited to a refund of the registration fee. The Society for Neuro-Oncology reserves the right to limit the number of participants at the meeting and will not be responsible for expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

Hotel Information

Program Committee Scientific Chair

E. Antonio Chiocca, MD, PhD

Education Day ChairsBalveen Kaur, PhD

Vinay Puduvalli, MD

Quality of Life ChairMichael J. Glantz, MD

Scientific CommitteeKen Aldape, MD

Manish Aghi, MD, Tracy Batchelor, MD,

Etty (Tika) Benveniste, PhD Michael Berens, PhD Markus Bredel, PhD Jeffrey Bruce, MD

Daniel Cahill, MD, PhD Arnab Chakravarti, MD

Charles Eberhart, MD, PhD Peter Forsyth, MD

Maryam Fouladi, MDJuan Fueyo, MD

Evanthia Galanis, MD David Gutmann, MD

Eric Holland, MD, PhD Mark Johnson, MD, PhD

Balveen Kaur, PhD Maciej (Matt) Lesniak, MD

Min Li, PhD Linda Liau, PhD

Russell Lonser, MDElizabeth Maher, MD, PhD

Andrew Parsa, MD, PhD Scott Plotkin, MD, PhD

Vinay Puduvalli, MDJeremy Rich, MD

John Sampson, MD, PhD Mariano Viapiano, PhD

Michael Vogelbaum, MD, PhD William Weiss, MD, PhD

Gelareh Zadeh, MD

Located in the heart of Washington DC, the Washington Hilton hotel is situated in the capital’s most sought after neighborhoods. Enjoy the best entertainment and nightlife Washington has to offer at the nearby Adams Morgan, Woodley Park and the U Street Corridor. This Wash-ington hotel is one mile from the Smithsonian National Zoo and only four blocks from Dupont Circle Metro. Easy access to iconic Washington attractions including the White House, the National Monument and the Lincoln Memorial. To book your room at the reduced conference rate of $189.00, visit www.soc-neuro-onc.org.

Educational DayThursday, November 15, 2012

Targeted Therapies Against Primary Brain Tumors Education Day SessionCo-Chairs: Vinay Puduvalli, Balveen Kaur

8:00-8:15 am Education Day: Introduction and Welcome Vinay Puduvalli, Balveen Kaur

Signal Transduction Agents Session Chairs: Vinay Puduvalli, Frank Furnari

8:15-8:35 am Growth Factor Inhibitors: Rationale, Clinical Experience and Challenges Ingo Mellinghoff

8:35-8:55 am Angiogenesis Therapies: Bevacizumab and Beyond Timothy Cloughesy

8:55-9:15 am Targeting the PI3K/AKT/mTOR Axis W. K. Alfred Yung

9:15-9:35 am Novel Molecular Targets for Therapy of Brain Tumors Paul Mischel

9:35-9:50 am Q & A

9:50-10:10 am Break

ImmunotherapySession Chairs: Maria Castro, Amy Heimberger

10:10-10:30 am Vaccine Strategies Duane Mitchell

10:30-10:50 am Immunotoxins for Glioma Therapeutics: Preclinical to Clinical Implementation Maria Castro

10:50-11:10 am Engineered T Cell Approaches Christine Brown

11:10-11:30 am Targeting CTLA-4 Glioma-mediated Immune Suppression Mark Gilbert

11:30-11:50 am Q & A

12:00-1:00 pm Boxed Lunches in the Foyer

Biological Therapies and Stem CellsSession Chairs: Balveen Kaur, Maciej Lesniak

1:00-1:20 pm Oncolytic Viruses Juan Fueyo

1:20-1:40 pm Peptide Therapy Wadih Arap 1:40-2:00 pm Targeting the Tumor Stem Cell: Rationale and Clinical Relevance Jeremy Rich

2:00-2:20 pm Stem Cell-Mediated Cancer Therapy – First in Human Clinical Trial for Glioma Karen Aboody

2:20-2.35 pm Q & A

2:35-2.50 pm Interactive Audience Quiz Session

7:00-9:00 am Breakfast in the Foyer

3:00-3:15 pm Break

SNO Course on the Basics of Biomarkers 2012Supported by the National Brain Tumor SocietyCourse Directors: Susan Chang, Kenneth Aldape

3:00-3:20 pm Overview of Biomarkers Martin Van den Bent

3:20-3:40 pm Imaging Biomarkers Whitney Pope

3:40-4:05 pm Biomarker Development and Validation from a Biostatistical Perspective Annette Molinaro 4:05-4:25 pm Translating Findings from TCGA into Clinical Biomarkers Jason Huse

4:25-4:45 pm Biomarkers and Antiangiogenic Therapy Manish Aghi

4:45-5:05 pm Biomarker Driven Early Clinical Trials and the Potential Role in Drug Development David Reardon

5:05-5:25 pm Biomarkers and Clinical Care: are we there yet? Michael Weller

Industry Sponsored Symposium: CNS Cancer Tumor Board: Clinical Investigators Provide Perspectives on Current Cases from Their PracticesNot sponsored by The University of Texas MD Anderson Cancer Center 5:30-7:30 pm

7:30-10:00 pm Welcome Reception

Supported by the American Brain Tumor Association

8:00-8:10 am Introduction Michael Glantz, Chair

8:10-8:55 am Measuring quality of life and recognizing impairment in neuro-oncology patients Tobias Walbert, Martin Klein

8:55-9:30 am Meeting of two minds: How close is the bench to the bedside? Jorg Dietrich

9:30-10:15 am Quality of life in neuro-oncology: How we started, where we’ve been, and the challenges that lay ahead Victor Levin, William Shapiro

10:15-10:30 am Break

Cutting Edge Therapy to Improve Quality of Life in Patients With Primary and Metastatic Brain Tumors

10:30-11:05 am Symptom Management – An Instructional Manual, Part I Glen Stevens

11:05-11:30 am Symptom Management - An Instructional Manual, Part II Jennie Rexer

11:30-12:00 pm Evidence-based medicine meets quality of life in neuro-oncology Edward Shaw

12:00-1:00 pm Boxed Lunches in the Foyer

Quality of Life/Symptom Management Concurrent Education Day Session Thursday, November 15, 2012

6:30-9:00 am Breakfast in the Foyer

7:00-8:00 am Sunrise Sessions

EANO and SNO Joint Session: From Guidelines To New Trials in Low Grade Gliomas: The American and European Views Riccardo Soffietti, Mark Gilbert, moderators• What is the role of awake surgery? Guy McKhann II, Hugues Duffau • What is the role of chemotherapy? David Schiff, Riccardo Soffietti

NF2 Update: Hearing Restoration and Foundations for the Future Scott Plotkin, moderator• Current Treatment for Neurofibromatosis 2-related acoustic neuroma: Observation, Surgery, and Radiation Therapy Frederick Barker• Anti-VEGF drug Therapy for NF2-related vestibular schwan-

noma: Endpoints and Results Scott Plotkin• Restoring Sound Perception to the Deaf Patient: Brainstem

and Cochlear Implants William Slattery• Molecular Targets and Foundations for Future Trials Jaishri Blakeley

Energetics and Metabolism Mariano Viapiano, moderator• Molecular sensors of metabolism (AMPK) Elizabeth Maher• Cytochrome c oxidase: Emerging mitochondrial target to

overcoming chemoresistance in gliomas Corinne Griguer• An Evaluation of IDH1 Mutant Metabolic Alterations as a

Therapeutic Target in GBM Gregory Riggins

Re-engineered T Cells and Bone Marrow Cells Robert Carter, moderator• New Approaches to Cellular Immunotherapy of Glioblastoma Steven Rosenberg• MGMTP140K-mediated chemoprotection in patients with

glioblastoma Hans-Peter Kiem• Other targets Robert Carter

Official Opening of MeetingFriday, November 16, 2012

Morning Plenary Session

8:10 am Introduction and Welcome E. Antonio Chiocca, Scientific Meeting Program Chair

Public Service Award: Edward G. Shaw

8:30-11:00 am Plenary Session 1 Top Scoring Abstracts: Basic Science

8:30 am AI-21 Spatiotemporal Regulation of GBM Neo-vascularization and Response to Therapy ADULT TRANSLATIONAL RESEARCH WINNER Gelareh Zadeh8:45 am SC-04 Know thy enemy: the development of imaging models to interrogate the complexity of cancer stem cells in malignant brain tumors ADULT BASIC SCIENCE AWARD CO-WINNER Justin D. Lathia9:00 am TM-06 Development of pediatric glioma models for BRAF-targeted therapy PEDIATRIC TRANSLATIONAL AWARD WINNER Shih-Shan Lang9:15 am PL-02 Molecular characterization of mutated histone H3.3 in pediatric glioblastoma PEDIATRIC BASIC SCIENCE AWARD WINNER Sebastian Bender 9:30 am ET-27 A novel class of small molecules prevent glioma growth and inhibit HIF binding to transcription co-factors p300/CBP Erwin G. Van Meir 9:45 am SC-41 Cortical GFAP+ astrocytes as a potential cellular origin of GBM ADULT BASIC SCIENCE AWARD CO-WINNER Ralf S. Schmid

10:00 am Break

10:15 am ME-03 New low frequency risk loci in the 8q24.21 (CCDC26) region are strongly associated with risk of oligodendroglial tumors and IDH1/2 mutated astrocytomas EPIDEMIOLOGY AWARD WINNER Robert B. Jenkins10:30 am CB-60 Cytomegalovirus enhances glioblastoma proliferation via STAT3 activation Richard L. Price

10:45 am Abhijit Guha Award Introduction

10:50 am Abhijit Guha Award: James Rutka

11:20 am Keynote Lecture Introduction

11:30 am Keynote Lecture: Bert Vogelstein

Noon- 1:00 pm Boxed Lunches in the Foyer Industry Supported Event Lymphomatous Meningitis Not supported by The University of Texas MD Anderson Cancer Center

Young Investigator Roundtable Luncheon Pre-registration via SNO website required

1:00-3:00 pm Concurrent Session 2A Medical, Neuro- and Radiation Oncology

1:00 pm NO-75 RO4929097 in Combination with Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma (MG): a Pharmacokinetic (PK) and Pharmacodynamic (PD) Study Antonio Omuro1:15 pm NO-56 RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas - updated survival and progression free survival analysis Michael A. Vogelbaum1:30 pm NO-62 Patterns of Treatment and Survival of GBM Patients with Diabetes Mellitus Chao Yin1:45 pm PA-22 Adult pilocytic astrocytoma: clinical features and molecular analysis Benjamin Ellezam2:00 pm NO-97 Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy David E. Piccioni2:15 pm IT-12 Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme David G. Walker2:30 pm NO-49 Final report for evaluable patients treated on DM92-035, phase III randomized study of post-irradiation PCV versus DFMO-PCV, for anaplastic gliomas (AG) Victor A. Levin2:45 pm NO-85 Antibody mediated anti-EGF-R therapy with nimotuzumab for newly diagnosed glioblastoma : Correlative analysis of the OSAG-101 phase III study results Manfred Westphal

1:00-3:00 pm Concurrent Session 2B Basic Sciences

1:00 pm AI-03 JAK-1/2 Inhibition Impairs Bone Marrow Derived Cell Recruitment Preventing Low to High Grade Glioma Transformation Prajwal Rajappa

1:15 pm CB-38 Unexpected nuclear sublocalization of the tyrosine kinase receptor Tie2 induces radioresistance of malignant gliomas Candelaria Gomez-Manzano1:30 pm IR-02 IDO expression suppresses anti-tumor immunity through a T cell-dependent mechanism Derek A. Wainwright1:45 pm MP-01 Astrocyte-elevated gene-1 (AEG-1) is Induced by Hypoxia and Glucose Deprivation and Modulates the Glycolytic Phenotype in Glioblastoma Evan Noch2:00 pm PL-16 Blockade of T cell transforming growth factor-beta signaling mitigates medulloblastoma progression in transgenic mice Rachelle Levy2:15 pm RB-01 Bromodomain protein Brd4 insulates chromatin from DNA damage signaling and is associated with glioblastoma resistance to radiation Clark C. Chen2:30 pm IR-15 Enhancement of dendritic cell migration to vaccine-site draining lymph nodes as a means to generate potent anti-tumor immune responses Kristen Batich 2:45 pm SC-34 CD133 inheritance depicts asymmetric cell division and the generation of tumor heterogeneity Masahiro Hitomi

3:00 pm Break

3:15-5:00 pm Concurrent Session 3A Symptom Management, Neuro-cognitive and Quality of Life Patrick Wen, moderator

3:15 pm Effects of Chemotherapy Jorge Dietrich American Academy of Neurology invited speaker3:30 pm Effects of Radiotheraphy (TBN), American Academy of Neurology invited speaker 3:45 pm SM-27 EANO/SNO TRAVEL SCHOLARSHIP AWARD WINNER Augmenting quality of life and mastery of informal caregivers of high-grade glioma patients: A randomized controlled trial Florien Boele, Amsterdam4:00 pm SM-19 Symptoms in Adult Long-Term Survivors of Malignant Brain Tumors Christina M. Amidei

4:15 pm NC-07 Long-term survivorship in primary glioblastoma: a focus on neurocognition Katherine B. Peters4:30 pm NC-08 Memantine for the Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy (WBRT): First Report of RTOG 0614, a Placebo-Controlled, Double-Blind, Randomized Trial Jeffrey S. Wefel4:45 pm NC-11 Magnetic Resonance Imaging associates with differences in neurocognitive performance for cancer survivors complaining of cognitive deficits following brain irradiation Ann M. Peiffer

3:15-5:00 pm Concurrent Session 3B

Molecular Epidemiology, -Omics and Prognostic Markers

3:15 pm ME-07 Integrated genomic analysis of glioblastoma: an update from The Cancer Genome Atlas Roel Verhaak3:30 pm MP-07 Metabolic modulation of glioblastoma (GBM) by depleting Hexokinase II (HK2): potentiating the effect of standard therapies Alenoush Vartanian3:45 pm ME-09 Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma Yanhong Liu4:00 pm OM-06 Genome Diversity Within a Child’s Medulloblastoma Melanie Hayden Gephart4:15 pm OM-03 IDH/MGMT-driven molecular classification is a strong predictor for low-grade glioma patient survival Jean-Louis Boulay4:30 pm OM-07 Genomic Characterization of Meningiomas Priscilla Brastianos4:45 pm OM-10 Circulating microvesicles in serum of GBM patients; could they became a new diagnostic tool? Marta M. Alonso

5:00-7:00 pm Management of 1p/19q codeleted anaplastic gliomas This symposium will discuss the updated results of the available phase II and III trials, how patients should now be managed, what role biomarkers have in patient selection, the choice of chemotherapy regimen and the design of the ongoing trials (including CODEL and CATNON).

7:00-9 :00pm Poster Viewing Reception

Saturday, November 17, 2012

6:30-9:00 am Breakfast in the Foyer

7:00-8:00 am Sunrise Sessions

Asian Society for Neuro-Oncology Session Ryo Nishikawa, moderator

• Toward understanding the pathogenesis of intracranial germ cell tumors

Koichi Ichimura• Vasculogenic mimicry: Alternative target for glioma treatment

Zhong-Ping Chen• Clinical, molecular correlation and translational study on CNS

AT/RT Tai-Tong Wong• Opportunities and challenges in neuro-oncology practice in

India Rakesh Jalali• Current PRC reviewed protocols and open clinical trials in KSNO Ho-Shin Gwak

The CMV and Glioma Connection Chang-Hyuk Kwon, moderator

• RNA-pulsed Dendritic Cells Targeting CMV Antigens in GBM Duane Mitchell• Cytomegalovirus infection accelerates malignant gliomas Chang-Hyuk Kwon• Cytomegalovirus- A Resident and Active Promoter of Glioma

Stem Cells Liliana Soroceanu

Mechanisms of Glioblastoma Immuno-evasion David Reardon, moderator

• Gordon Freeman • Andrew Parsa• STAT3 as a molecular hub of glioma-mediated immune sup-

pression and tumorigenesis Amy Heimberger• Peter Fecci

Pituitary Tumors: Biology and Treatment Manmeet Ahluwalia, moderator

• Pituitary adenoma biology and genetics Russell Lonser• Surgical Management of Pituitary Tumors Edward Laws• Radiosurgery for Pituitary Tumors Douglas Kondziolka

Morning Plenary Session

8:15-9:45 am Pediatric Minisymposium Session 4

8:15 am Introduction

8:30 am Pediatric Glioblastoma: a tale of a histone tail Nada Jabado

8:50 am Molecular Pathogenesis of Diffuse Intrinsic Pontine Glioma Suzanne Baker

9:10 am Metastatic Medulloblastoma is a Bicompartmental Disease Secondary to Clonal Selection Michael Taylor

9:30 am Ependymoma Stefan Pfister

9:50 am Q & A

10:00 am Break

10:15am-Noon Plenary Session 5

Clinical Studies 1

10:15 am NO-06 MGMT promoter methylation predicts benefit from temozolomide versus radiotherapy in malignant astrocytomas in the elderly: the NOA-08 trial ADULT CLINICAL RESEARCH AWARD CO-WINNER Michael Weller10:30 am NO-64 Clinical course and progression free survival of adult and pedriatic ependymoma: a working model Elizabeth Vera-Bolanos10:45 am OT-03 Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAglio ADULT CLINICAL RESEARCH AWARD CO-WINNER Olivier Chinot 11:00 am MR-03 Long term follow up of EORTC 26951, a randomized trial on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors. A report of the EORTC BTG Martin J. van den Bent

11:15 am RT-09 To compare the treatment outcomes of two different target volume delineation guidelines (RTOG vs M.D. Anderson) in glioblastoma multiforme patients: A prospective randomized study Narendra Kumar

11:30 am Introduction to Victor Levin Lecture

11:40 am Victor Levin Lecture Gregory Cairncross Robert Jenkins

Noon Boxed Lunches in the Foyer

SNO Business Meeting

2:45 pm CB-53 An in vivo loss of function screen for genes involved in EGFRvIII-independent glioma growth Tiffany E. Taylor

1:00-3:00 pm Concurrent Session 6B

Epidemiology, Pathology and Radiology

1:00 pm PA-09 Histological predictors of outcome in ependymoma are dependent on tumor location in the central nervous system Aditya Raghunathan1:15 pm PA-21 Anti-angiogenic therapy increases tumor associated macrophages (TAMs) in recurrent glioblastoma (GBM) patients Christine Lu-Emerson1:30 pm PA-08 BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper Fausto J. Rodriguez1:45 pm PA-18 Patterns of repressive histone 3 lysine 9 trimethylation (H3K9me3) in gliomas with and without isocitrate dehydrogenase 1 R132H mutation. Sriram Venneti2:00 pm RA-17 Imaging-genomic Necrosis Mapping Reveals Gender-specific Survival and Molecular Determinants in GBM Rivka R. Colen2:15 pm EP-12 Gender and Racial Risk Factors for Childhood Brain Tumors Cynthia J. Campen2:30 pm OM-23 Prognostic or predictive value of MGMT promoter methylation in malignant gliomas depends on IDH1 mutations Wolfgang Wick2:45 pm RA-05 EANO/SNO TRAVEL SCHOLARSHIP AWARD WINNER Signal intensity in preoperative diffusion-weighted imaging correlates with survival times in patients with single brain metastasis Anna Sophie Berghoff, Vienna

3:00-3:15 pm Break

Afternoon Concurrent Sessions

1:00-3:00 pm Concurrent Session 6A

Cell Biology and Signaling

1:00 pm CB-32 Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma Erwin G. Van Meir1:15 pm CB-35 Ectopic overexpression of miR145 compromises the invasive ability of malignant gliomas by modulating NEDD9 Maria Carmela Speranza1:30 pm TM-12 The potential male-specific oncogenic function of Cdca7l in astrocytoma Min-Hyung Lee1:45 pm SC-15 MSH6 mutations arise in malignant glioma both prior to and following chemoradiotherapy and contribute to temozolomide resistance independently of MGMT promoter methylation Stephanie A. Nguyen2:00 pm SC-27 Identification of novel therapeutic targets through an integrated in vitro and in vivo whole genome shRNA screen in glioma stem cells Simone P. Niclou2:15 pm SC-03 Genome-wide transcriptome analysis defines two mutually-exclusive glioma stem cell subtypes with distinctive clinical features Ping Mao2:30 pm CB-48 Notch Ligands, Lateral Inhibition and Stem-like Glioblastoma Cells Kah Jing Lim

3:15-5:00 pm Concurrent Session 7A

Angiogenesis and Invasion

3:15 pm AI-09 Hypoxia Upregulates MiR-451 Expression in Gliomas David Zagzag3:30 pm CB-57 Phosphorylation of Dock180Y722 by Src Family Kinases Mediates EGFRvIII-Driven Glioblastoma Tumorigenesis Shiyuan Cheng

3:45 pm CB-16 Stress-regulated expression of miR-451 controls proliferation/migration dichotomy of glioblastoma in vitro and in vivo impacting radio- and chemo-response Daisuke Ogawa4:00 pm SC-16 Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity Youngmi Kim4:15 pm CB-03 Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling Mariano S. Viapiano4:30 pm RB-14 Invasion and proliferation kinetics predict IDH-1 mutation in contrast-enhancing gliomas Anne L. Baldock4:45 pm AI-24 VEGF Blockade results in Epithelial Mesenchymal transition in Glioblastoma Viviane Tabar

3:15-5:00 pm Concurrent Session 7B

Surgery and Immunology

3:15 pm IR-18 Adoptive transfer immunotherapy targeting NY-ESO-1 for treatment of glioblastoma Richard G. Everson 3:30 pm IR-07 S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages Leying Zhang 3:45 pm IR-17 Tumor-infiltrating lymphocytes in glioblastoma are associated with NF1, TP53, and RB1 mutations and the mesenchymal transcriptional subtype William C. Rutledge4:00 pm NS-03 Never say never: Risk factors for, and consequences of hospital acquired never events in neuro-oncologic surgery Brad E. Zacharia4:15 pm NS-15 Complications and outcomes in recurrent glioma surgery Ian F. Parney4:30 pm IT-23 Vemurafenib and radiation therapy in melanoma brain metastasis Ashwatha Narayana4:45 pm IT-13 WT1 peptide vaccination for newly diagnosed glioblastomas; phase I clinical trial of combination with temozolomide Naoya Hashimoto

Sunday, November 18, 2012

5:00-7:00 pm Poster Viewing Reception

7:15-10:00 pm Banquet

6:30-9:00 am Breakfast in the Foyer

7:00-8:00 am Sunrise Sessions

Oncolytic Viruses: Clinical Trials Update Evanthia Galanis, moderator

• Oncolytic measles strains in GBM treatment: an update Evanthia Galanis• Delta-24-RGD adenovirus: ongoing hopes and challenges Juan Fueyo• Toca511 Nori Kasahara• Clinical Trials of HSV-1 for Glioma Jim Markert

The Radiobiology of CNS Tumors Gelareh Zadeh, moderator

• Targeting vasculogenesis: A new paradigm for the treatment of brain tumors

Martin Brown• Radiation Biology Essentials Richard Hill• Molecular Determinants of Radiation Response and Toxicity Arnab Chakravrarti• Microenvironmental influences on the radiation response of

brain John Fike

The Biology of Brain Metastases Peter Forsyth, moderator

• Rakesh Jain• Deeper insights into the crucial steps of brain metastasis

Frank Winkler• Molecular and Preclinical Advances in Brain Metastasis of

Breast Cancer Brunilde Gril

MicroRNA Biology in CNS Tumors Sean Lawler, moderator

• Novel anti-apoptotic onco-miRs in glioblastoma stem-like cells Benjamin Purow• Mark Johnson• Jakub Godlewski• Peripheral micro RNA biomarkers for primary and metastatic

brain tumors Anne Krichevsky

Morning Plenary Session

8:15-10:45 am Plenary Session 8

Clinical Studies 2

8:15 am PC-05 Final Report of Outcome of the CCG-99703 Children’s Oncology Group Study for Children Less Than 3 Years of Age Newly-Diagnosed with Malignant PEDIATRIC CLINICAL RESEARCH AWARD WINNER Jonathan Finlay 8:30 am NS-13 Complete, but not partial resection is important in the era of radiotherapy, concomitant and adjuvant temozolomide for glioblastoma patients Jörg-Christian Tonn8:45 am IT-01 Peptide vaccine therapy for childhood gliomas: Updated Results of a Pilot Study Ian F. Pollack9:00 am EP-09 An exploratory gene-environment-wide interaction study (GEWIS) of childhood medulloblastoma survival Michael E. Scheurer9:15 am MR-02 A revised RTOG Recursive Partitioning Analysis (RPA) model for glioblastoma based upon multi-platform biomarker profiles Arnab Charkravarti9:30 am NC-04 Hippocampus as a dose constraint model to preserve neurocognition in young patients with low-grade brain tumors treated with focal stereotactic conformal radiotherapy: data from a prospective clinical trial QUALITY OF LIFE AWARD WINNER Rakesh Jalali9:45 am NO-82 Bevacizumab given with temozolomide and radiation therapy (RT) in newly diagnosed patients with glioblastoma multiforme (GBM) reduces the chance of early radiologic progression Lloyd M. Alderson

10:00 am Break

10:15 am OM-21 Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant PCV chemotherapy in anaplastic oligodendroglial brain tumors. A report from EORTC study 26951 Pim French

10:30 am IT-20 Dendritic Cell Vaccines Targeting Human Cytomegalovirus in Glioblastoma Reveal Lymph Node Homing as Major Axis for Clinical Intervention Duane A. Mitchell

10:45-1145 am RANO Session

10:45 am Welcome

10:50 am Validation of the RANO recommendations Summary of Wick and Gerstner efforts

11:00 am Ongoing efforts RAPNO, Mets, Meningioma

11:20 am Discussion of use of TTP versus 6 mo PFS as endpoints for recurrent GBM studies Summary of Chang and Wu talks

11:30 am Opportunities for future efforts Discussion of process

11:40 am Open discussion

12:00 pm Adjourn

12:00-2:30 pm Career Development and Networking Session Lunchprovided.PreregistrationviaSNO website required.

7:00-8:00 am SNO Highlights Session (By invitation only)

Membership is available at 3 levels: Full, Associate, and Trainee. Full membership requires doctorate-level degree. Associate memberships are available for those without doctorate-level degrees, whose work involves neuro-oncol-ogy-related practice or research. Trainee memberships are available to those in scientific or clinical training who do not hold faculty appointments.

Full or Associate memberships are $200.00 per year; Trainee memberships are $75 per year.

Members receive the following benefits: • Twelve monthly issues of Neuro-Oncology • Discount to the annual SNO Scientific Meeting and Education Day • Regular e-blasts and neuro-oncology news • Access to members-only section of the SNO website

Visit: www.soc-neuro-onc.org to join.

Join SNO!

Society for Neuro-Oncology4617 Birch Street, Bellaire, TX 77401-5509Tel: 713-349-0952 E-Fax: 832-201-8129

www.soc-neuro-onc.org